RxDoctor Payments Data

Prashant Barakoti, MD

Internal Medicine · Norfolk, VANPI 1801011598

Payments from drug & device makers

$16,885in general payments, 2019–2025

Across 676 payments — averaging $24.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • AbbVie$2K
  • Amgen$2K
  • Novo Nordisk$2K
  • Lilly USA, LLC$1K
  • Pfizer$1K
  • plus $6K from 51 others

What the payments were for

  • Food & beverage$16,876100%
  • Education$90%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca59$2,498
AbbVie(2 entities)101$2,134
Amgen50$1,766
Novo Nordisk60$1,697
Lilly USA, LLC71$1,428
Pfizer61$1,109
Johnson & Johnson28$907
GSK32$853
Biohaven Pharmaceutical Holding Company Ltd.16$527
Boehringer Ingelheim25$418
Eisai Inc.6$239
Amarin Pharma, Inc.13$223
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC14$210
Bayer10$202
Corcept Therapeutics5$199
Exact Sciences10$197
Neurocrine Biosciences, Inc.3$180
Takeda Pharmaceuticals U.S.A., Inc.12$170
Idorsia Pharmaceuticals US Inc4$169
Merck10$167
Abbott7$150
Astellas Pharma US Inc8$142
Novartis8$129
Ardelyx, Inc.1$112
Esperion Therapeutics, Inc.6$107
Currax Pharmaceuticals LLC6$93
Actelion Pharmaceuticals US, Inc.5$85
Jazz Pharmaceuticals Inc.4$85
Antares Pharma, Inc.3$44
Boston Scientific3$42
Biohaven Pharmaceuticals, Inc.2$42
Sunovion Pharmaceuticals Inc.2$41
Innovation Technologies Inc2$36
Ultragenyx Pharmaceutical Inc.2$36
E.r. Squibb & Sons, L.L.C.2$35
Insulet Corporation1$35
Endo Pharmaceuticals Inc.2$33
Avanir Pharmaceuticals, Inc.2$28
Daiichi Sankyo Inc.1$25
Sanofi Pasteur Inc.1$24
Cranial Technologies, Inc1$22
Kyowa Kirin, Inc.1$22
Supernus Pharmaceuticals, Inc.1$20
Bardy Diagnostics, Inc.2$19
Inari Medical, Inc.1$18
Sanofi-aventis U.S. LLC1$17
Shire North American Group Inc1$16
Arbor Pharmaceuticals, Inc.1$15
Myriad Genetic Laboratories, Inc.1$15
Metuchen Pharmaceuticals1$14
Genentech USA, Inc.1$14
Lupin Inc.1$13
Gilead1$13
Assertio Therapeutics, Inc.1$12
Mylan Specialty L.p.1$12
Hikma Pharmaceuticals USA1$12
Kowa Pharmaceuticals America, Inc.1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,885 in reported general payments places this provider in the 95th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$134,599
Medicare patients
449
Services billed
1,960

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide36$72,248
EliquisApixaban71$64,610
FarxigaDapagliflozin Propanediol38$45,846
JardianceEmpagliflozin33$42,260
JanuviaSitagliptin Phosphate52$33,998
XareltoRivaroxaban22$26,149
RybelsusSemaglutide13$15,643
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$9,312
InvokametCanagliflozin/Metformin Hcl11$6,469
Atorvastatin Calcium337$2,873
SynthroidLevothyroxine Sodium19$2,252
Metoprolol Succinate166$2,247
Rosuvastatin Calcium141$2,197
Potassium Chloride32$2,126
Losartan Potassium231$1,965

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,697$87,89049 claims
PfizerEliquis$1,109$64,61071 claims
AstraZenecaFarxiga$2,498$45,84638 claims
Boehringer IngelheimJardiance$418$42,26033 claims
MerckJanuvia$167$33,99852 claims
Johnson & JohnsonXarelto, Invokamet$907$32,61833 claims
AbbVieSynthroid$2,134$2,25219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Norfolk

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →